SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel (INTC) is trending following a mixed earnings report and cautious forward guidance, leading to a significant pullback. While many in the community debate high valuation metrics and ongoing competition with peers like NVDA and AMD, others remain optimistic, emphasizing the company's strategic importance in the US semiconductor manufacturing push and temporary supply constraints as a "high-class problem."

RYVYL Inc. is a financial technology company that develops software platforms and tools that are focused on providing global payment acceptance and disbursement capabilities. It offers an innovative payment platform-as-a-service that redefines global payment solutions, enabling seamless business-to-business, consumer-to-business, and peer-to-peer transactions worldwide. The company leverages advanced electronic payment technology to deliver seamless financial solutions across global markets. It operates through two geographical segments: North America and International. The company was founded on April 10, 2007 and is headquartered in San Diego, CA.

Ryvyl Inc

Ryvyl (RVYL) is trending as its merger with Roundtable/RTB Digital advances, highlighted by recent S-4 filings and progress toward NASDAQ compliance, including a significant strategic partnership for Roundtable. The community is actively discussing a potential short squeeze, driven by the stock's exceptionally low public float and perceived undervaluation, anticipating substantial upside from the combined entity's Web3 digital media platform and Bitcoin treasury elements.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune (ALT) is commanding attention as its Breakthrough Therapy Designation for pemvidutide in MASH and obesity ignites intense community speculation around a potential buyout or strategic partnership. With significant short interest, many investors are actively discussing the possibility of a major rerating or acquisition by a pharmaceutical giant, viewing the stock as currently undervalued within the thriving GLP-1 sector.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing significant trending activity following reports of robust early prescription data for its new oral weight-loss medication, which the community views as a substantial market advantage. Investors are highly optimistic about the company's position as a leader in the expanding oral GLP-1 sector, anticipating a re-evaluation of its valuation amid strong demand.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as the community eagerly discusses the finalized deal for a US joint venture involving TikTok, where Oracle plays a pivotal role in cloud infrastructure and security. Many anticipate this could drive significant new revenue and solidify Oracle's standing in the AI and sovereign cloud sectors, though some maintain caution regarding the broader impact on its valuation and existing debt.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano is currently experiencing a significant surge following news of its all-stock merger with AI cloud computing firm Corvex, which also announced a long-term NVIDIA H200 GPU deployment. This has ignited strong community discussion, with many anticipating a short squeeze and parabolic price movement due to the stock's notably low float. However, some traders are urging caution, highlighting that the NVIDIA news relates to GPU usage rather than a direct partnership and pointing to potential dilution.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is generating significant buzz due to its extremely low share float, fueling intense speculation around a potential short squeeze. While many in the community are anticipating a rapid, parabolic breakout, others caution against a pump-and-dump scheme, citing the company's publicly acknowledged strategic review and discontinued operations. This dynamic has positioned SNSE as a highly volatile micro-cap, attracting traders focused on short-term, speculative price movements.

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

60 Degrees Pharmaceuticals Inc

SXTP is currently trending due to its announced partnership with Runway Health, which will expand access to its malaria prevention drug, ARAKODA, via a telehealth platform. This news, coupled with the stock's low float and recent reverse split, is fueling intense community discussion about its potential for a short squeeze and sustained upward momentum. While many traders are celebrating significant gains, some express caution regarding the stock's volatility and the possibility of future dilution.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corporation is trending due to anticipation surrounding upcoming regulatory decisions for its inhaled insulin Afrezza, including a label update and pediatric approval, alongside strong quarterly revenue performance. Community discussion centers on the potential for increased market penetration and significant pipeline advancements, with many speculating about future collaborations or a potential acquisition given the value of its Technosphere platform and expanding product offerings.

Movement Network is a secure and scalable blockchain designed to make Move programming accessible to developers everywhere. With high-performance execution and security, Movement delivers the infrastructure for the next generation of decentralized applications and unleashes opportunity and financial empowerment for anyone, anywhere.  $MOVE is the native token of Movement Network, for transaction fees and staking to secure the network. The Movement M1 (Layer 1) Network is powered by the Move programming language, unleashing opportunity, accessibility, and financial empowerment for anyone, anywhere.

MarketMove

MarketMove is trending due to the planned all-stock merger between Movano and Corvex, with Corvex recently announcing a significant long-term NVIDIA H200 GPU deployment for an AI-driven battery technology provider. The community is actively discussing the implications of this move into AI infrastructure, with high volatility and speculation around short squeeze potential driving conversation, despite some concerns regarding the merger's terms for existing shareholders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CRVO these are awful
One of the worst bio stock and board that I have seen

László István Németh

$CRVO looks like that they have already reached out to some people to see if an offering is possible